olutasidenib capsules is a prescription medicine used to treat relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation

enasidenib is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.

Idelalisib is a prescription medicine used to treat adults with: Chronic Lymphocytic Leukemia (CLL) Chronic Lymphocytic Leukemia (CLL) in combination with rituximab when CLL comes back after prior cancer treatment and when Rituxan treatment alone may be used due to other health problems.

omacetaxine mepesuccinate for Injection is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI). This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with omacetaxine mepesuccinate.

Ivosidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by FDA-approved test with Acute Myeloid Leukemia & Locally Advanced or Metastatic Cholangiocarcinoma.

Facilitating Access to Approved MedicationMethylprednisolone Injection Active Ingredient(s): MethylprednisoloneTrade Name: On RequestPackaging: TabletsStrength: Tablets may vary from 4 mg to 48 mg of methylprednisoloneIndications:...

Facilitating Access to Approved MedicationGlasdegib Tablets Active Ingredient(s): Glasdegib TabletsTrade Name: On RequestPackaging: TabletsStrength: Tablets: 100 mg, 25 mg.Indications: Glasdegib is indicated, in combination with low-dose...

Facilitating Access to Approved MedicationInotuzumab Ozogamicin For Injection Active Ingredient(s): Inotuzumab Ozogamicin For InjectionTrade Name: On RequestPackaging: InjectionStrength: For injection: 0.9 mg lyophilized powder in a single-dose...

Facilitating Access to Approved MedicationNilotinib Capsules Active Ingredient(s): Nilotinib CapsulesTrade Name: On RequestPackaging: CapsulesStrength: 2.5 milligram tabletsIndications: Nilotinib is used to treat Philadelphia chromosome...

Midostaurin was approved by the FDA On April 28, 2017 for the treatment of adult patients with newly diagnosed AML who are positive for oncogenic FLT3, in combination with chemotherapy The drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML.